Placenta Accreta Spectrum

Predicting placenta accreta spectrum and high postpartum hemorrhage risk using radiomics from T2-weighted MRI

BACKGROUND

Antenatal diagnosis of placenta accreta spectrum (PAS) is of critical importance, considering that women have much better outcomes when delivery occurs at a level III or IV maternal care facility before labor initiation or bleeding, thus avoiding placental disruption. Herein, we aimed to investigate the performance of magnetic resonance imaging (MRI) in antenatal prediction of PAS and postpartum hemorrhage (PPH).

METHODS

This retrospective study included 433 women with singleton pregnancies (PAS group, n = 208; non-PAS group, n = 225; PPH-positive (PPH (+)) group, n = 80; PPH-negative (PPH (-)) group, n = 353), who were randomly divided into a training set and a test set in a 7:3 ratio. Radiomic features were extracted from T2WI (T2-weighted imaging). Features strongly correlated with PAS and PPH (p < 0.05) were selected using Pearson correlation, followed by LASSO regression for dimensionality reduction. Subsequently, radiomics models were constructed for PAS and PPH risk prediction, respectively. Regression analyses were conducted using radiomics score (R-score) and clinical factors to identify independent clinical risk factors for PAS and PPH, leading to the development of corresponding clinical models. Next, clinical-radiomics models were built by combining R-score and clinical risk factors. The predictive performance of the models was evaluated using nomograms, calibration curves, and decision curves.

RESULTS

The clinical-radiomics models and radiomics models for predicting PAS and PPH risk both outperformed their clinical models in the training and testing sets. For PAS, the AUC (Area Under the Receiver Operating Characteristic Curve) of the clinical-radiomics model, radiomics model, and clinical model in the training set are 0.918, 0.908, and 0.755, respectively, and in the testing set, the AUCs are 0.885, 0.866, and 0.771, respectively. For PPH, the AUCs of the clinical-radiomics model, radiomics model, and clinical model in the training set are 0.918, 0.884, and 0.723, respectively, and in the testing set, the AUCs are 0.905, 0.860, and 0.688, respectively. The DeLong test p-values between the clinical-radiomics models and radiomics models for predicting PAS and PPH are both less than 0.05. Additionally, in the testing set, the clinical-radiomics models perform best in predicting PAS and PPH risk, with accuracies of 82.31% and 84.61%, respectively.

CONCLUSION

This novel clinical-radiomics model has a robust performance in predicting PAS antepartum and predicting massive PPH in pregnancies.

Association between congenital uterine anomalies and placenta accreta spectrum

Objective

To evaluate the association between congenital uterine anomalies (CUAs) and placenta accreta spectrum (PAS) in a large, nationally representative sample.

Design

Cross-sectional, observational study using the US National Inpatient Sample from 2017 to 2021. Logistic regression models were constructed to evaluate associations between the exposure and the outcome. Predetermined confounding variables included age, history of a cesarean delivery, and placenta previa. A sensitivity analysis was performed including only patients with a code for placenta accreta spectrum who also underwent hysterectomy. Data were weighted according to National Inpatient Sample complex sampling weights to account for year-to-year variation and to extrapolate estimates to the US population.

Subjects

Pregnant patients at ≥20 weeks' gestation with International Classification of Disease codes for congenital uterine anomalies or PAS.

Exposure

Code for at least 1 of the CUAs.

Main Outcome Measures

Code for at least 1 of the types of PAS during delivery hospitalization.

Results

The study cohort included 17,594,765 (or 3,518,955 unweighted) individuals. CUAs were present in 78,809 (0.45%, 15,259 unweighted) individuals. PAS was more frequent in patients with CUA than in those without (0.42% vs. 0.12%), with a weighted odds ratio (OR) of 3.36 (95% confidence interval [CI], 2.62-4.32; unweighted OR, 3.37 [95% CI, 2.63-4.31]). When controlling for age, prior cesarean, and placenta previa, the odds of having PAS was higher in those with a CUA than in those without (weighted adjusted OR [aOR], 2.46 [95% CI, 1.87-3.17]; unweighted aOR, 2.44 [95% CI, 1.88-3.16]). In the sensitivity analysis including only individuals with PAS who underwent a hysterectomy, CUA continued to be associated with PAS (weighted aOR, 2.26 [95% CI, 1.52-3.36]; unweighted aOR, 2.26 [95% CI, 1.55-3.31]).

Conclusion

In this population-based study, CUAs were associated with an increased odds of PAS. Patients with CUA should have careful screening for PAS at the time of routine obstetric ultrasound.

Nationwide Assessment of Gestational Age Distribution at Delivery for Patients With Placenta Accreta Spectrum Disorder

OBJECTIVE

To assess the distribution of gestational age at delivery for patients with placenta accreta spectrum (PAS) in the United States.

METHODS

This serial cross-sectional study examined 26,375 hospital deliveries with a diagnosis code for PAS identified in the Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project National Inpatient Sample from 2016 to 2021. Descriptive analysis was performed to evaluate the distribution of gestational age at delivery of patients with PAS and related obstetric characteristics. The incidence of PAS codes was also assessed among 21,212,493 hospital deliveries.

RESULTS

The majority of patients with PAS delivered preterm (before 37 weeks of gestation, 56.9%); 43.1% delivered at term (37 weeks of gestation or more). Compared with patients with PAS who had preterm deliveries, those with PAS who had term deliveries were more likely to deliver vaginally (32.0% vs 6.9%) and in a rural-setting (9.7% vs 2.3%) or small-bed-capacity (18.6% vs 8.4%) hospital and were less likely to have placenta previa (9.3% vs 50.5%) and increta and percreta subtypes (8.6% vs 27.4%) (all P<.001). Incidences of hemorrhage or blood transfusion or both (62.9% vs 71.5%), shock or coagulopathy or both (6.2% vs 9.8%), hysterectomy (25.6% vs 65.3%), urinary tract injury (2.5% vs 10.0%), and maternal mortality (0.0% vs 0.2%) were lower for patients with PAS who had term compared with preterm deliveries (all P<.001). When any hospital deliveries were included in the analysis, 1 in every 804 delivering patients had a diagnosis of PAS. The incidence sharply decreased from 1 in 83-300 hospital deliveries in the preterm period to 1 in 705-3,037 hospital deliveries after 37 weeks of gestation. The incidence of PAS increased by 15.4% (95% CI, 10.7-20.4), from 114.8 to 132.5 per 100,000 hospital deliveries during the 6-year study period (P trend<.001).

CONCLUSION

In this nationwide, cross-sectional study in the United States, nearly 40% of patients with PAS delivered at term and had distinct clinical and obstetric characteristics and outcomes compared with patients with PAS who delivered preterm. Continued increase in the incidence of PAS at the national level calls for attention and evaluation.

Pregnancy Outcomes after Uterine Preservation Surgery for Placenta Accreta Spectrum: A Retrospective Cohort Study

OBJECTIVE

 This study aimed to investigate maternal and neonatal outcomes in subsequent pregnancies of women with a history of placenta accreta spectrum (PAS) compared with women without history of PAS.

STUDY DESIGN

 A retrospective cohort study conducted at a single tertiary center between March 2011 and January 2022. We compared women with a history of PAS who had uterine preservation surgery and a subsequent pregnancy, to a control group matched in a 1:5 ratio. The primary outcome was the occurrence of a composite adverse outcome (CAO) including any of the following: uterine dehiscence, uterine rupture, blood transfusion, hysterectomy, neonatal intensive care unit admission, and neonatal mechanical ventilation. Multivariable logistic regression was performed to evaluate associations with the CAO.

RESULTS

 During the study period, 287 (1.1%) women were diagnosed with PAS and delivered after 25 weeks of gestation. Of these, 32 (11.1%) women had a subsequent pregnancy that reached viability. These 32 women were matched to 139 controls. There were no significant differences in the baseline characteristics between the study and control groups. Compared with controls, the proportion of CAO was significantly higher in women with previous PAS pregnancy (40.6 vs. 19.4%, p = 0.019). In a multivariable logistic regression analysis, previous PAS (adjusted odds ratio [aOR] = 3.31, 95% confidence interval [CI] = 1.09-10.02, p = 0.034) and earlier gestational age at delivery (aOR = 3.53, 95% CI = 2.27-5.49, p < 0.001) were independently associated with CAOs.

CONCLUSION

 A history of PAS in a previous pregnancy is associated with increased risk of CAOs in subsequent pregnancies.

KEY POINTS

· The uterine-preserving approach for PAS delivery is gaining more attention and popularity in recent years.. · Women with a previous pregnancy with PAS had higher rates of CAOs in subsequent pregnancies.. · Previous PAS pregnancy is an independent factor associated with adverse outcomes..

Predicting the risk of cesarean hysterectomy in the management of placenta accreta spectrum disorders: a new model based on clinical findings and ultrasonography

PURPOSE

To develop a nomogram to predict the probability of cesarean hysterectomy (CH) in placenta accreta spectrum disorders (PASD) patients.

METHODS

Data from 520 patients who underwent surgery with a preliminary diagnosis of PASD at a tertiary center in southeast Turkey between 2013 and 2023 were collected, and 302 patients were included in the study. A predictive model based on clinical and ultrasonographic variables was developed using penalized maximum likelihood estimation (PMLE) regression analysis.

RESULTS

Maternal age (aOR = 1.22, 95% CI 1.08-1.44, p = 0.001) and prior uterine surgeries (aOR = 3.18, 95% CI 1.57-8.29, p = 0.001) were identified as demographic factors with an increased likelihood of CH in the nomogram, and advanced gestational weeks demonstrated a negative correlation (aOR: 0.78, 95% CI 0.56-1.02, p = 0.07). Regarding the ultrasonographic findings, the presence of the "multiple lacunae within the placenta" (aOR = 48.53, 95% CI 18.42-257.40, p < 0.001) and the "anterior placental location" (aOR = 9.60, 95% CI 2.96-50.76, p < 0.001) significantly increased the probability of CH. In addition, "hypervascularization on Doppler flow with irregularity in the line between the bladder and uterine serosa" (aOR = 7.90, 95% CI 2.66-35.12, p < 0.001) and the "retroplacental myometrial thickness of < 1 mm" (aOR = 2.49, 95% CI 0.89-8.27, p = 0.08) were related to the probability of CH. Harrell's C-index was 0.974, and the kappa value was 0.819 for the prediction model's performance evaluation.

CONCLUSION

We developed a nomogram to predict the probability of cesarean hysterectomy in patients with PASD, incorporating maternal age, gestational weeks, prior uterine surgeries, ultrasound findings, and placental location. The most closely associated findings with CH in patients with PASD were the presence of multiple placental lacunae and the anterior location of the placenta.

Early first-trimester transvaginal ultrasound screening for cesarean scar pregnancy in patients with previous cesarean delivery: analysis of the evidence

Obstetric hemorrhage is a leading cause of maternal morbidity and mortality. An important etiology of obstetric hemorrhage is placenta accreta spectrum. In the last 2 decades, there has been increased clinical experience of the devastating effect of undiagnosed, as well as late diagnosed, cases of cesarean scar pregnancy. There is a growing body of evidence suggesting that cesarean scar pregnancy is an early precursor of second- and third-trimester placenta accreta spectrum. As such, cesarean scar pregnancy should be diagnosed in the early first trimester. This early diagnosis could be achieved by introducing regimented sonographic screening in pregnancies of patients with previous cesarean delivery. This opinion article evaluates the scientific and clinical basis of whether cesarean scar pregnancy, with special focus on its early first-trimester discovery, complies with the accepted requirements of a screening test. Each of the 10 classical screening criteria of Wilson and Jungner were systematically applied to evaluate if the criteria were met by cesarean scar pregnancy, to analyze if it is possible and realistic to carry out screening in a population-wide fashion.

Effect of pelvic artery embolization for postpartum hemorrhage on subsequent pregnancies: a single-center retrospective cohort study

OBJECTIVE

Pelvic artery embolization (PAE) is a uterus-saving treatment for postpartum hemorrhage (PPH); however, subfertility or abnormal placentation for subsequent pregnancy has been a concern in several previous reports. This study aimed to investigate the impact of PAE on subsequent pregnancies in women with a history of PPH.

METHODS

A retrospective cohort study was conducted on women transferred to the tertiary center for PPH and delivered for the next pregnancy at the same center later. The study group was divided into two groups based on PAE application to treat previous PPH.

RESULTS

Of the 62 women included, 66% (41/62) had received PAE for the previous PPH, while 21 had not. Pregnancy outcomes for subsequent pregnancies were compared between the PAE and non-PAE groups. The PAE group had a higher estimated blood loss volume for the present delivery than the non-PAE group (600 vs. 300 mL, p = 0.008). The PAE group also demonstrated a higher incidence of placenta previa (4.8% vs. 24.4%, p = 0.080) and placenta accreta (0% vs. 14.6%, p = 0.082) than the non-PAE group, although the difference was not statistically significant.

CONCLUSION

These findings suggest that the use of PAE to treat PPH may increase the risk of bleeding, placenta previa, and placenta accreta spectrum in subsequent pregnancies.

A prediction model based on MRI and ultrasound to predict the risk of PAS in patient with placenta previa

INTRODUCTION

To investigate the risk factors affecting patients with placenta previa (PP) and to construct an effective prediction model for the severity of PAS in PP.

METHODS

A total of 240 pregnant women with PP were enrolled in this study. An MRI+Ultrasound-based model was developed to classify patients into placental implantation and non-placental implantation groups. Multivariate nomograms were created based on imaging features. The model was evaluated using Receiver Operating Characteristic (ROC) curve analysis. The predictive accuracy of the nomogram was assessed through calibration plots and decision curve analysis.

RESULTS

The MRI+Ultrasound-based prediction model demonstrated favorable discrimination between the placental implantation and non-placental implantation groups. The calibration curve exhibited agreement between the estimated and actual probability of placental implantation. Additionally, decision curve analysis indicated a high clinical benefit across a wide range of probability thresholds. The Area under the ROC curve (AUC) was 0.911 (95 % CI: 0.76-0.947), with a sensitivity of 88.40 % and specificity of 88.10 %.

CONCLUSION

The MRI+Ultrasound-based prediction model could be a valuable tool for preoperative prediction of the percentage of implantation. Our study enables obstetricians to conduct more adequate preoperative evaluations.

Prophylactic Radiologic Interventions for Postpartum Hemorrhage Control in Women With Placenta Accreta Spectrum Disorder: A Systematic Review and Meta-analysis

OBJECTIVE

To quantify the association between prophylactic radiologic interventions and perioperative blood loss during cesarean delivery in women with placenta accreta spectrum disorder through a systematic review and network meta-analysis.

DATA SOURCES

On January 3, 2023, a literature search was conducted in PubMed, EMBASE, Cochrane Library, and Web of Science. We also checked ClinicalTrials.gov retrospectively. Prophylactic radiologic interventions to reduce bleeding during cesarean delivery involved preoperative placement of balloon catheters, distal (internal or common iliac arteries) or proximal (abdominal aorta), or sheaths (uterine arteries). The primary outcome was volume of blood loss; secondary outcomes were the number of red blood cell units transfused and adverse events. Studies including women who received an emergency cesarean delivery were excluded.

METHODS OF STUDY SELECTION

Two authors independently screened citations for relevance, extracted data, and assessed the risk of bias of individual studies with the Cochrane Risk of Bias in Non-randomized Studies of Interventions tool.

TABULTATION, INTEGRATION, AND RESULTS

From a total of 1,332 screened studies, 50 were included in the final analysis, comprising 5,962 women. These studies consisted of two randomized controlled trials and 48 observational studies. Thirty studies compared distal balloon occlusion with a control group, with a mean difference in blood loss of -406 mL (95% CI, -645 to -167). Fourteen studies compared proximal balloon occlusion with a control group, with a mean difference of -1,041 mL (95% CI, -1,371 to -710). Sensitivity analysis excluding studies with serious or critical risk of bias provided similar results. Five studies compared uterine artery embolization with a control group, all with serious or critical risk of bias; the mean difference was -936 mL (95% CI, -1,522 to -350). Reported information on adverse events was limited.

CONCLUSION

Although the predominance of observational studies in the included literature warrants caution in interpreting the findings of this meta-analysis, our findings suggest that prophylactic placement of balloon catheters or sheaths before planned cesarean delivery in women with placenta accreta spectrum disorder may, in some cases, substantially reduce perioperative blood loss. Further study is required to quantify the efficacy according to various severities of placenta accreta spectrum disorder and the associated safety of these radiologic interventions.

SYSTEMATIC REVIEW REGISTRATION

PROSPERO, CRD42022320922.

Maternal outcomes of conservative management and cesarean hysterectomy for placenta accreta spectrum disorders: a systematic review and meta-analysis

BACKGROUND

Cesarean hysterectomy as a traditional therapeutic maneuver for placenta accreta spectrum (PAS) has been associated with serious morbidity, conservative management has been used in many institutions to treat women with PAS. This systematic review aims to compare maternal outcomes according to conservative management or cesarean hysterectomy in women with placenta accreta spectrum disorders.

METHODS

A systematic literature search was performed in MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Web of Science, and four Chinese databases (Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Chinese Wanfang database and VIP database) to May 2024. Included studies were to be retrospective or prospective in design and compare and report relevant maternal outcomes according to conservative management (the placenta left partially or totally in situ) or cesarean hysterectomy in women with PAS. A risk ratio (RR) with 95% confidence interval (95% CI) was calculated for categorical outcomes and weighted mean difference (WMD) with 95% CI for continuous outcomes. The Newcastle-Ottawa Quality Assessment Scale was used to assess the observational studies. All analyses were performed using STATA version 18.0.

RESULTS

Eight studies were included in the meta-analysis. Compared with cesarean hysterectomy, PAS women undergoing conservative management showed lower estimated blood loss [WMD - 1623.83; 95% CI: -2337.87, -909.79], required fewer units of packed red blood cells [WMD - 2.37; 95% CI: -3.70, -1.04] and units of fresh frozen plasma transfused [WMD - 0.40; 95% CI: -0.62, -0.19], needed a shorter mean operating time [WMD - 73.69; 95% CI: -90.52, -56.86], and presented decreased risks of bladder injury [RR 0.24; 95% CI: 0.11, 0.50], ICU admission [RR 0.24; 95% CI: 0.11, 0.52] and coagulopathy [RR 0.20; 95% CI: 0.06, 0.74], but increased risk for endometritis [RR 10.91; 95% CI: 1.36, 87.59] and readmission [RR 8.99; 95% CI: 4.00, 12.21]. The incidence of primary or delayed hysterectomy rate was 25% (95% CI: 19-32, I2 = 40.88%) and the use of uterine arterial embolization rate was 78% (95% CI: 65-87, I2 = 48.79%) in conservative management.

CONCLUSION

Conservative management could be an effective alternative to cesarean hysterectomy when women with PAS desire to preserve the uterus and are informed about the limitations of conservative management.

PROSPERO ID

CRD42023484578.

Cesarean hysterectomy for placenta accreta spectrum: 3-2-1 approach

Given the high risk of complications associated with cesarean hysterectomy for placenta accreta spectrum (PAS), any surgical approach and technique can yield utility in reducing the surgical morbidity. Here, we propose the 3-2-1 approach as a schema to be implemented in the proper setting for the surgical management of a PAS cesarean hysterectomy. The 3-2-1 approach begins with the surgical dissection of three anatomical landmarks that ultimately facilitate a safe surgical site for the ligation and transection of the uterine vessels. First-step is identification of the three anatomical landmarks which are (i) posterior lower uterine segment peritoneum de-serosalization, (ii) identification of the ureters laterally, and (iii) anterior bladder dissection. Posterior-to-anterior progression avoids encountering dense adhesions and hypervascularity in the anterior lower uterine segment early in the surgery. Further, allows better mobilization of the uterus to identify the anatomical landmarks laterally and anteriorly. Second-step is to deploy the 2-hand technique where the surgeon places one hand anteriorly and the other hand posteriorly in the lower uterine segment below the placental bed. The surgeon brings both hands together with flexed fingers perpendicular to the uterine tissue and gently elevates the uterus and placenta out of the pelvis and ensures safe anatomical distance to surrounding structures. Third-step is the consideration of a supracervical hysterectomy. In summary, this 3-2-1 approach to reflect the anatomy of enlarged lower uterine segment in PAS is a stepwise schema that can aid surgeons in the completion of a cesarean hysterectomy, with the goal to improve surgical outcomes.

Addressing Diagnosis, Management, and Complication Challenges in Placenta Accreta Spectrum Disorder: A Descriptive Study

INTRODUCTION

In light of increased cesarean section rates, the incidence of placenta accreta spectrum (PAS) disorder is increasing. Despite the establishment of clinical practice guidelines offering recommendations for early and effective PAS diagnosis and treatment, antepartum diagnosis of PAS remains a challenge. This ultimately risks poor mental health and poor physical maternal and neonatal health outcomes.

CASE DESCRIPTIONS

This case series details the experience of two high-risk patients who remained undiagnosed for PAS until they presented with antenatal hemorrhage, leading ultimately to necessary, complex surgical interventions, which can only be optimally provide in a tertiary care center. Patient 1 is a 37-year-old woman with a history of three cesarean sections, which elevates her risk for PAS. She had placenta previa detected at 19 weeks, and placenta percreta diagnosed upon hemorrhage. During a hysterectomy, invasive placenta was found in the patient's bladder, leading to a cystotomy and right ureteric reimplantation. After discharge, she was diagnosed with a vesicovaginal fistula, and is currently awaiting surgical repair. Patient 2 is a 34-year-old woman with two previous cesarean sections. The patient had complete placenta previa detected at 19- and 32-week gestation scans. She presented with antepartum hemorrhage at 35 weeks and 2 days. An ultrasound showed thin myometrium at the scar site with significant vascularity. A hysterectomy was performed due to placental attachment issues, with significant blood loss. Both patients were at high risk for PAS based on past medical history, risk factors, and pathognomonic imaging findings.

DISCUSSION

We highlight the importance of the implementation of clinical guidelines at non-tertiary healthcare centers. We offer clinical-guideline-informed recommendations for radiologists and antenatal care providers to promote early PAS diagnosis and, ultimately, better patient and neonatal outcomes through increased access to adequate care.

Placenta accreta spectrum disorder at single-cell resolution: a loss of boundary limits in the decidua and endothelium

BACKGROUND

Placenta accreta spectrum disorders are associated with severe maternal morbidity and mortality. Placenta accreta spectrum disorders involve excessive adherence of the placenta preventing separation at birth. Traditionally, this condition has been attributed to excessive trophoblast invasion; however, an alternative view is a fundamental defect in decidual biology.

OBJECTIVE

This study aimed to gain insights into the understanding of placenta accreta spectrum disorder by using single-cell and spatially resolved transcriptomics to characterize cellular heterogeneity at the maternal-fetal interface in placenta accreta spectrum disorders.

STUDY DESIGN

To assess cellular heterogeneity and the function of cell types, single-cell RNA sequencing and spatially resolved transcriptomics were used. A total of 12 placentas were included, 6 placentas with placenta accreta spectrum disorder and 6 controls. For each placenta with placenta accreta spectrum disorder, multiple biopsies were taken at the following sites: placenta accreta spectrum adherent and nonadherent sites in the same placenta. Of note, 2 platforms were used to generate libraries: the 10× Chromium and NanoString GeoMX Digital Spatial Profiler for single-cell and spatially resolved transcriptomes, respectively. Differential gene expression analysis was performed using a suite of bioinformatic tools (Seurat and GeoMxTools R packages). Correction for multiple testing was performed using Clipper. In situ hybridization was performed with RNAscope, and immunohistochemistry was used to assess protein expression.

RESULTS

In creating a placenta accreta cell atlas, there were dramatic difference in the transcriptional profile by site of biopsy between placenta accreta spectrum and controls. Most of the differences were noted at the site of adherence; however, differences existed within the placenta between the adherent and nonadherent site of the same placenta in placenta accreta. Among all cell types, the endothelial-stromal populations exhibited the greatest difference in gene expression, driven by changes in collagen genes, namely collagen type III alpha 1 chain (COL3A1), growth factors, epidermal growth factor-like protein 6 (EGFL6), and hepatocyte growth factor (HGF), and angiogenesis-related genes, namely delta-like noncanonical Notch ligand 1 (DLK1) and platelet endothelial cell adhesion molecule-1 (PECAM1). Intraplacental tropism (adherent versus non-adherent sites in the same placenta) was driven by differences in endothelial-stromal cells with notable differences in bone morphogenic protein 5 (BMP5) and osteopontin (SPP1) in the adherent vs nonadherent site of placenta accreta spectrum.

CONCLUSION

Placenta accreta spectrum disorders were characterized at single-cell resolution to gain insight into the pathophysiology of the disease. An atlas of the placenta at single cell resolution in accreta allows for understanding in the biology of the intimate maternal and fetal interaction. The contributions of stromal and endothelial cells were demonstrated through alterations in the extracellular matrix, growth factors, and angiogenesis. Transcriptional and protein changes in the stroma of placenta accreta spectrum shift the etiologic explanation away from "invasive trophoblast" to "loss of boundary limits" in the decidua. Gene targets identified in this study may be used to refine diagnostic assays in early pregnancy, track disease progression over time, and inform therapeutic discoveries.

Clinical Risk Factors for Placenta Accreta or Placenta Percreta: A Case-Control Study

OBJECTIVES

Uterine scarring is a risk factor for placenta accreta spectrum (PAS) disorder. We aimed to determine the factors related to PAS in women who had previously undergone a cesarean.

METHODS

We performed a case-control study where women who underwent postpartum hysterectomy for placenta accreta/percreta (cases) were matched to all women with a previous cesarean who delivered in the week before each case (controls). Maternal characteristics along with previous cesarean characteristics were compared between cases and controls. Univariate and multivariate logistic regression analyses were performed to determine risk factors related to PAS.

RESULTS

We compared 64 cases of PAS that required hysterectomy to 192 controls. The factors related to PAS were a history of uterine surgery (OR 27.4; 95% CI 5.1-146.5, P < 0.001) and the number of previous cesareans (2 cesareans: OR 7.2; 95% CI 3.4-15.4, P < 0.001; more than 2 cesareans: OR 7.9; 95% CI 2.9-21.5, P < 0.001). In women with a single previous cesarean without previous uterine surgery, an interdelivery interval of fewer than 18 months (OR 6.3; 95% CI 1.8-22.4, P = 0.004) and smoking (OR 5.8; 95% CI 1.2-27.8, P = 0.03) were related to PAS. The gestational age and the cervical dilatation at previous cesarean were not associated with PAS (all with P > 0.05). The lack of data regarding the closure of the uterus at previous cesareans prevents us from drawing solid conclusions.

CONCLUSIONS

Previous uterine surgery, the number of previous cesareans, smoking, and an interdelivery interval of fewer than 18 months after cesarean are significant risk factors for PAS requiring postpartum hysterectomy.

Association of Paternal Age Alone and Combined with Maternal Age with Perinatal Outcomes: A Prospective Multicenter Cohort Study in China

Maternal and paternal age at birth is increasing globally. Maternal age may affect perinatal outcomes, but the effect of paternal age and its joint effect with maternal age are not well established. This prospective, multicenter, cohort analysis used data from the University Hospital Advanced Age Pregnant Cohort Study in China from 2016 to 2021, to investigate the separate association of paternal age and joint association of paternal and maternal age with adverse perinatal outcomes. Of 16,114 singleton deliveries, mean paternal and maternal age (± SD) was 38.0 ± 5.3 years and 36.0 ± 4.1 years. In unadjusted analyses, older paternal age was associated with increased risks of gestational diabetes mellitus (GDM), hypertensive disorders of pregnancy, preeclampsia, placenta accreta spectrum disorders, placenta previa, cesarean delivery (CD), and postpartum hemorrhage, preterm birth (PTB), large-for-gestational-age, macrosomia, and congenital anomaly, except for small-for-gestational-age. In multivariable analyses, the associations turned to null for most outcomes, and attenuated but still significant for GDM, CD, PTB, and macrosomia. As compare to paternal age of < 30 years, the risks in older paternal age groups increased by 31-45% for GDM, 17-33% for CD, 32-36% for PTB, and 28-31% for macrosomia. The predicted probabilities of GDM, placenta previa, and CD increased rapidly with paternal age up to thresholds of 36.4-40.3 years, and then plateaued or decelerated. The risks of GDM, CD, and PTB were much greater for pregnancies with younger paternal and older maternal age, despite no statistical interaction between the associations related to paternal and maternal age. Our findings support the advocation that paternal age, besides maternal age, should be considered during preconception counseling.Trial Registration NCT03220750, Registered July 18, 2017-Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT03220750 .